Business Activities
Pipeline
We are developing a 'cell therapy that treats the underlying causes of incontinence' using the a patients' own cells.
We are currently engaged in the development and commercialization of the following three cell therapy pipelines targeting fecal incontinence and urinary incontinence.
Development Code
Target Indication
Cell Type
Research and Development Stage
- Preclinical
-
Clinical Trial
- Phase I
- Phase II
- Phase III
- Drug Approval
- Commercialization
ICEF15
urge fecal incontinence
autologous skeletal muscle-derived cells
- Preclinical
- Phase I
- Phase II
- Phase III
- Drug Approval
- Commercialization
ICEF16
passive fecal incontinence
autologous skeletal muscle-derived cells
- Preclinical
- Phase I
- Phase II
- Phase III
- Drug Approval
- Commercialization
ICES13
stress urinary incontinence
autologous skeletal muscle-derived cells
- Preclinical
- Phase I
- Phase II
- Phase III
- Drug Approval
- Commercialization